✦ LIBER ✦

Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma A report of the Children's Cancer Group

✍ Scribed by Warren P. Mason; Stewart Goldman; Allan J. Yates; James Boyett; Hao Li; Jonathan L. Finalay

Book ID: 110230985
Publisher: Springer US
Year: 1998
Tongue: English
Weight: 46 KB
Volume: 37
Category: Article
ISSN: 0167-594X
DOI: 10.1023/a:1005980206723

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of pre-irradiation chemot

Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: A report from the Children's Oncology Group

✍ James H. Garvin Jr.; Michael T. Selch; Emi Holmes; Mitchell S. Berger; Jonathan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

A Phase II study of carboplatin as a tre

A Phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow : A report of the Children's Cancer Group

✍ Lawrence J. Ettinger; Percy Ivy; Paul S. Gaynon; Alice G. Ettinger; Wen Liu-Mare 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 3 views

## BACKGROUND. Carboplatin is an analogue of cisplatin with less nonhematologic toxicity

Regimen-related toxicity of myeloablativ

✍ Grovas, Alfred C.; Boyett, James M.; Lindsley, Karen; Rosenblum, Marc; Yates, Al 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Background. The survival of children with glioblastoma multiforme (GBM) remains poor. In an effort to improve the cure rate of children with this disease, high-dose chemotherapy followed by autologous stem cell rescue (ASCR) has been evaluated. We report the regimenrelated toxicity (RRT) and surviva

A Phase I study of granulocyte-macrophag

A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group

✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 3 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a